Heart News and Research

RSS

Celera reports net revenue of $34.9 million for fourth quarter of 2010

Celera Corporation today reported net revenues of $34.9 million for the fourth quarter of 2010 that ended December 25, 2010, compared to $39.2 million for the prior year quarter.

18 Mar 2011

Medicare officials signal no payment changes on anemia drugs

Medicare officials signaled Wednesday that they will not change a payment policy for biotech drugs made by Amgen and Johnson & Johnson when they are used to treat anemia in kidney disease patients, despite data suggesting heart risks for those patients.

18 Mar 2011

Science journal publishes CYTK preclinical cardiac myosin activation research results

Cytokinetics, Incorporated announced today the publication of preclinical research in the March 18, 2011 issue of the journal Science regarding the activation of cardiac myosin by an investigational drug candidate, omecamtiv mecarbil, and the potential therapeutic role that this novel mechanism may play for patients with systolic heart failure.

18 Mar 2011

U-M researcher endorses new concepts designed to improve kidney allocation

Providing kidney transplants to patients with the best probability of longer survival would reduce repeat transplant operations and improve life span after kidney transplant, says a U-M researcher in a commentary published in the New England Journal of Medicine March 16.

18 Mar 2011

JHUSON adds Harvey the Cardiopulmonary Simulator to simulation education

It's official: Harvey the Cardiopulmonary Simulator checked in for an extended stay at the Johns Hopkins University School of Nursing (JHUSON) last month. Harvey is the latest addition to the School's upgraded simulation laboratories and the newest member of the "Sim Fam." These life-like practice manikins, including Sim Man, Vital Sim Man,Noelle with newborn, and Sim Baby give nursing students the hands-on experience without the anxiety of working with actual human beings.

18 Mar 2011

Pilot study shows feasibility of heart screening for risk of SCA in children

A pilot study in healthy children and adolescents shows that it is feasible to screen for undiagnosed heart conditions that increase the risk of sudden cardiac arrest.

18 Mar 2011

Major clinical studies for heart disease, stroke fail to consider participant's ethnicity

Major clinical studies that evaluate prevention strategies for heart disease and stroke fail to consider a participant's ethnicity, a factor that can more than double the rate of death in some groups, according to research led by St. Michael's Dr. Joel Ray.

18 Mar 2011

Stem cell therapy can reduce heart size, scar tissue and improve function in cardiac patients

Researchers have shown for the first time that stem cells injected into enlarged hearts reduced heart size, reduced scar tissue and improved function to injured heart areas, according to a small trial published in Circulation Research: Journal of the American Heart Association.

18 Mar 2011

British pie, mash and gravy meals too salty: Heart health experts

A new study by Consensus Action on Salt and Health (CASH) in the UK that looked at 526 pie, mash and gravy meals and products, found some meals to be extremely high in salt. A chicken and mushroom pie with chips or mash, gravy and peas from pub chain Wetherspoons contained an alarming 7.5g of salt, well over the daily maximum recommendation of 6g a day. All the pie and mash pub meals looked at contained more than 3g, half the daily maximum, the report said. The survey, conducted by YouGov, found that the mashed potato and gravy could significantly increase the salt content of a meal. According to CASH, while good progress has been made by supermarkets in cutting salt levels in pies, there are still too many products containing unnecessary quantities of salt.

17 Mar 2011

Stem cell therapy successfully heals a scarred and failing heart

A new study has shown that stem cells could heal scars caused by old heart attacks. In all eight patients who received the experimental treatment in an ongoing clinical trial this therapy worked. All of them had suffered heart attacks an average of 5 1/2 years prior; one of the patients had his heart attack 11 years earlier.

17 Mar 2011

Sports medicine physician suggests cardiac screening for young athletes requires augmentation of existing diagnostics to achieve greater accuracy, become cost-effective

Sports medicine physician Steve Watts says cardiac screening for young athletes is useful in preventing sudden cardiac death and suggests new diagnostics have the potential to add value and change the debate about the viability of cardiac screening for young athletes in the United States.

17 Mar 2011

TF3 consortium receives ECCH contract to provide RNTI

The TF3 consortium has been chosen to provide a Remote Telemonitoring Service to Northern Ireland which will support over 8,000 patients during the course of the contract.

17 Mar 2011

Major breakthrough in thrombosis

Scientists from the University of Reading have announced a major breakthrough in understanding how to control blood clotting which could lead to the development of new treatments and save the lives of thousands of people each year.

17 Mar 2011

Experts to review latest research on bariatric surgery at International summit

On March 28, leading experts across multiple disciplines will convene at the 2nd World Congress on Interventional Therapies for Type 2 Diabetes to review the latest research on bariatric surgery as a treatment option.

17 Mar 2011

Hazelden, Columbia University to open collegiate addiction recovery residence in N.Y. City

Hazelden, one of the world's largest and most respected private, nonprofit alcohol and drug addiction treatment centers, announced today that it will open a first-of-its-kind collegiate recovery residence called Tribeca Twelve in New York City's Tribeca neighborhood.

17 Mar 2011

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

PsiOxus Therapeutics, Ltd. announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated with significant morbidity and mortality.

17 Mar 2011

New policy research evaluates proposed reduction consequences in federal health center

A new policy research brief released today by the Geiger Gibson/RCHN Community Health Foundation Research Collaborative at The George Washington University School of Public Health and Health Services evaluates the consequences of the proposed reductions in federal health center funding for access and cost savings.

17 Mar 2011

Experts advise against taking unnecessary potassium iodide

There is a mad rush to the stores to pick up potassium iodide supplements to guard against radiation exposure wafting over to the U.S. from Japan, an unlikely event according to experts. This is despite health officials’ warnings that these supplements are pointless and could cause adverse side effects.

16 Mar 2011

Heart disease: The largest killer in Australia

According to a new federal government report, heart disease is the biggest killer in Australia, causing nearly 50,000 deaths a year.

16 Mar 2011

St. Jude Medical achieves 2 million mechanical heart valve implant milestone

St. Jude Medical, Inc., a global medical device company, today announced that the company will celebrate the treatment of more than 2 million patients with its mechanical heart valve technology. This milestone, a landmark achievement for prosthetic heart valves, demonstrates the company's commitment to cardiac surgery and improving patient outcomes.

16 Mar 2011